Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Lupartumab amadotin - Bayer HealthCare

Next Previous
Drug Profile

Lupartumab amadotin - Bayer HealthCare

Alternative Names: Anti-C4.4a antibody-drug conjugates - Bayer; Anti-LY6-PLAUR domain containing 3 antibody-drug conjugates - Bayer; Anti-LYPD3 antibody-drug conjugates - Bayer; BAY 1129980; LYPD3 protein-directed antibody-drug conjugates - Bayer

Latest Information Update: 29 Jul 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Bayer HealthCare
  • Class Antineoplastics; Auristatins; Drug conjugates; Immunoconjugates
  • Mechanism of Action LYPD3 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Solid tumours

Most Recent Events

  • 27 Nov 2018 Phase I development in Solid tumours is ongoing (Bayer pipeline, November 2018)
  • 28 Oct 2018 No recent reports of development identified for phase-I development in Solid-tumours(Late-stage disease) in Canada (IV)
  • 28 Oct 2018 No recent reports of development identified for phase-I development in Solid-tumours(Late-stage disease) in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Legal

Back to top